Table A1.
Adjusted* odds ratios of intermediate and advanced liver fibrosis by liver disease markers by AUDIT and phosphatidylethanol (PEth), stratified by hepatitis-c viral (HCV) status, NOAH study.
| Intermediate liver damage/fibrosis | Advanced liver fibrosis | |||||||
|---|---|---|---|---|---|---|---|---|
| ALT | AST | NAFLD-FS | APRI | FIB-4 | NAFLD-FS | APRI | FIB-4 | |
| Odds ratio (95% CI) | Odds ratio (95% CI) | |||||||
| AUDIT <8 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | |
| Moderate risk 8–16 | ||||||||
| All | 0.65 (0.33, 1.29) | 1.04 (0.43, 2.52) | 0.85 (0.41, 1.75) | 0.88 (0.41, 1.86) | 0.56 (0.26, 1.21) | 0.92 (0.27, 3.15) | 0.73 (0.12, 4.65) | 1.77 (0.47, 6.58) |
| HCV+ | 0.35 (0.10, 1.25) | 0.49 (0.12, 2.02) | 3.48 (0.62, 19.66) | 0.84 (0.23, 3.05) | 1.10 (0.21, 5.68) | 4.05 (0.31, 53.19) | - | 1.14 (0.11, 12.04) |
| HCV− | 0.81 (0.38, 1.75) | 1.61 (0.57, 4.57) | 0.63 (0.29, 1.39) | 0.83 (0.34, 2.05) | 0.47 (0.19, 1.14) | 0.66 (0.16, 2.66) | 1.70 (0.23, 12.45) | 3.67 (0.80, 16.93) |
| PEth <250 | Ref. | Ref. | Ref. | Ref. | ||||
| Any misuse 250–400 | ||||||||
| All | 3.83 (1.49, 9.83) | 7.70 (2.38, 24.94) | 1.45 (0.52, 4.04) | 4.86 (1.68, 14.11) | 3.33 (1.05, 10.56) | 1.99 (0.31, 12.67) | 25.39 (3.15, 205.08) | 17.52 (3.23, 95.18) |
| HCV+ | - | - | 0.39 (0.03, 5.79) | - | - | - | - | - |
| HCV− | 3.73 (1.38, 10.08) | 8.03 (2.20, 29.33) | 1.85 (0.59, 5.84) | 4.40 (4.31, 4.50) | 3.02 (0.92, 9.87) | 2.66 (0.39, 18.36) | 3.83 (3.67, 4.00) | 33.6 (4.00, 283.91) |
| PEth <250 | Ref. | Ref. | Ref. | Ref. | ||||
| ≥250 | ||||||||
| All | 2.60 (1.36, 5.00) | 5.00 (2.13, 11.69) | 3.28 (1.59, 6.79) | 4.13 (1.95, 8.75) | 3.71 (1.70, 8.14) | 4.57 (1.11, 18.87) | 20.23 (3.54, 115.48) | 17.92 (4.34, 74.01) |
| HCV+ | 0.83 (0.16, 4.21) | 1.78 (0.32, 10.02) | 4.33 (0.68, 27.69) | 1.79 (0.26, 12.10) | 14.54 (1.04, 203.45) | - | 19.98 (0.71, 559.91) | 8.52 (0.34, 215.46) |
| HCV− | 16.83 (2.46, 115.13) | 4.72 (2.14, 10.43) | 3.09 (1.56, 6.15) | 3.15 (1.45, 6.82) | 3.11 (1.37, 7.06) | 4.85 (1.13, 20.77) | 6.54 (2.53, 16.88) | 41.44 (6.48, 264.96) |
ALT = alanine aminotransferase; AST = aspartate aminotransferase; APRI = AST to platelet ratio index; FIB-4 = fibrosis-4; NAFLD FS = non-alcoholic fatty liver disease fibrosis score.
*All models adjusted for age, sex, BMI, hepatitis-B virus status, smoking status, viral load and lifetime drinking history.